Fast Absorbing PGLA
Riverpoint Medical, LLC · Decision date Sep 29, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for K263073, Fast Absorbing PGLA, on September 29, 2026, with the submission received September 1, 2026. The applicant is Riverpoint Medical, LLC of Portland, Oregon; the device falls under 21 CFR 878.4493, product code GAM, in the General and Plastic Surgery panel. The public record lists the review as a Special 510(k), not reviewed by a third party, and not a combination product. SE denotes clearance to market under general controls, not premarket approval.
The device is a braided, coated synthetic absorbable suture of polyglycolic-lactic acid with a poly(glycolide-co-L-lactide) and calcium stearate coating, supplied sterile for single use, with or without a needle. The summary identifies K120556 (Vilet Quick) as the predicate and states the only difference is labeling that adds a contraindication for ligation, ophthalmic, cardiovascular and neurological procedures. The indications enclosure limits use to superficial soft tissue approximation of skin and mucosa needing short-term wound support. The record does not disclose clinical outcome data or the basis for the 7-10 day support period.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Sep 29, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K263073
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Riverpoint Medical, LLC
- Product code
- GAM
- Decision code
- SESE
- Decision date
- Sep 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Suture, Absorbable, Synthetic, Polyglycolic Acid.
- Applicant
- Riverpoint Medical, LLC
- Product code
- GAM
- FDA device class
- 2
FDA decision timeline
K263073 received
Application receipt date recorded by FDA.
K263073 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Riverpoint Medical, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Portland, OR
Sources and methodology
- Original FDA record: K263073
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records